Location: Solmed Polyclinic (Zagreb)
Study Drug: Biological therapy that suppresses the excessive activity of B-lymphocytes that overly produce antibodies associated with this syndrome. The drug is already registered for the treatment of myasthenia gravis.
Main Inclusion Criteria: Patients over 18 years of age diagnosed with postural orthostatic tachycardia syndrome (POTS) after recovering from COVID-19.
Status: In preparation
Start of patient enrollment: August 2024.